

Abstract 223 Table 1 Summary of the clinicopathologic features by ProMisE molecular subtype

Variable	Total	POLEmut	MMRd	NSMP	p53abn
Total	172	21 (12.2%)	47 (27.3%)	74 (43.0%)	30 (17.4%)
Age at diagnosis					
<60 years	70 (40.7%)	12 (57.1%)	18 (38.3%)	38 (51.4%)	2 (6.6%)
≥60 years	102 (59.3%)	9 (42.9%)	29 (61.7%)	36 (48.6%)	28 (93.3%)
Histotype					
Endometrioid	137 (79.7%)	18 (85.7%)	45 (95.7%)	71 (95.9%)	3 (10.0%)
Non-endometrioid	35 (20.3%)	3 (14.3%)	2 (4.3%)	3 (4.1%)	27 (90.0%)
-Serous	15(8.7%)	0	1(2.1%)	0	14(46.7%)
-Clear cell	2(1.2%)	0	0	1(1.4%)	1(3.3%)
-Carcinosarcoma	8(4.7%)	0	0	0	8(26.7%)
-Mixed	10(5.8%)	3(14.3%)	1(2.1%)	2(2.7%)	4(13.3%)
Tumour grade					
low grade	129 (75%)	16 (76.2%)	41 (87.2%)	69 (93.2%)	2 (6.7%)
high grade	43 (25%)	5 (23.8%)	6 (12.8%)	5 (6.8%)	28 (93.3%)
Tumour size					
<2cm	31 (18.0%)	4 (19.0%)	12 (25.5%)	14 (18.9%)	1 (3.3%)
≥2cm	132 (76.8%)	17 (81.0%)	35 (74.5%)	53 (71.6%)	27 (90.0%)
unk	9 (5.2%)	0	0	7 (9.5%)	2 (6.7%)
Myoinvasion					
None	39 (22.7%)	5 (23.8%)	13 (27.7%)	16 (21.6%)	5 (16.7%)
<50%	82 (47.7%)	11 (52.4%)	19 (40.4%)	37 (50.0%)	15 (50%)
≥50%	51 (29.6%)	5 (23.8%)	15 (31.9%)	21 (28.4%)	10 (33.3%)
FIGO stage					
I-II	140 (81.4)	17 (81.0%)	43 (91.5%)	64 (86.5%)	15(50.0%)
III-IV	32 (18.6%)	4 (19.0%)	4 (8.5%)	10 (13.5%)	15 (50.0%)
LVI					
Negative	117 (68.0%)	15 (71.4%)	31(66.0%)	59 (79.7%)	12 (40.0%)
Positive	55 (32.0%)	6 (28.6%)	16 (34.0%)	15 (20.3%)	18 (60.0%)
Pelvic and Para-aortic LND					
Yes	171 (99.4%)	21 (100%)	47 (100%)	74 (100%)	29 (96.7%)
No	1 (0.6%)				1 (3.3%)
Presence of LN metastases	31 (18.1%)	3 (14.2%)	7 (14.9%)	8 (10.8%)	13 (44.8%)

LN, lymph node; LND, lymph node dissection; LVI, lymphovascular invasion; unk, unknown.

By multivariate analysis, molecular subtype and CA 125 >25 kU/L were significantly associated with LN metastases ($p=0.021$ and $p=0.022$ respectively) compared to histotype, which showed no significant association with LN status ($p=0.24$).

Conclusion* EC molecular subtype significantly associates with LN metastases and offers objective, reproducible, and prognostic information from diagnostic specimens. Pre-operative knowledge of molecular subtype can guide biologically-informed approaches to LN sampling, particularly for patients with high molecular risk (p53abn) EC.

230

THE ROLE OF PROGNOSTIC RISK FACTORS IN ENDOMETRIAL CANCER RECURRENCE: A RETROSPECTIVE STUDY

¹G Spagnol*, ²I Pezzani, ²G Corrao, ²S Gava, ²V Bernardini, ²S Kilzie, ³G Artioli, ¹G Bonaldo, ¹M Noventa, ¹S Carlo, ³E Busato. ¹Clinic of Gynecology and Obstetrics, University of Padua, Padua, Italy, Department of Women and Children's Health; ²Treviso Regional Hospital, Treviso, Italy, Department of Obstetrics and Gynecology; ³Treviso Regional Hospital, Treviso, Italy, Department of Oncology

10.1136/ijgc-2021-ESGO.127

Introduction/Background* Histopathologic type, grading, myometrial invasion, lymphovascular space invasion (LVSI) and

immunohistochemistry (POLEmt: POLE mutated; MMRd: mismatch repair deficient, p53abn: p53+) represent the main pathologic features to define the prognostic risk groups in endometrial cancer. This study aimed to evaluate the correlation between the prognostic factors and the rate of recurrence in our experience.

Methodology We conducted a monocentric retrospective study of consecutive women who underwent surgical treatment for endometrial cancer at Department of Gynecology Oncology, Treviso Regional Hospital, between January-2017 to October-2020. Baseline demographics, histopathologic type, grading, FIGO stage, LVSI, myometrial infiltration, lymph node involvement (LNI), and immunohistochemistry (when available) were collected. The diagnosis of recurrence and his pattern (distant or pelvic) were analyzed on the basis of prognostic factors type.

Result(s)* A total of 146 women were included: 105 patients in stage I (72%), 15 in stage II (10%), 22 in stage III (15%) and 4 in stage IV (3%). The rate of recurrence was 13% (19 patients) with a median time to recurrence of 15 months (3-42). A univariate approach showed a significantly association between recurrence and histopathologic non-endometrioid type (O.R 3.13; p=0.05), LNI (O.R 4.05; p=0.03), myometrial infiltration (O.R. 2.84; p=0.04), positive-LVSI (O.R. 3.32; p=0.01), grading (O.R. 3.9; p=0,0001), FIGO-stage (II O.R. 1.64; III O.R. 2.91; IV O.R. 10.20; p=0.03), and p53abn (O.R. 5.10; p=0.02). We found no significant differences between recurrence and MMRd (O.R. 0.90; p>0,8), no POLEmt was found in our recurrence patients. A positive-LVSI related with a distant recurrence (O.R 8.00; p=0.003). In multivariate analysis, FIGO stage and p53abn (OR=1.1 and OR=5.3; p-value=0.05, respectively) were found independent predictors factor for recurrence. In particular, all patients with p53abn and recurrence were in FIGO stage I at the diagnosis.

Conclusion* All prognostic factors related to recurrence, and FIGO-stage represented the most significant risk factor. Instead, when we considered immunohistochemistry, p53abn resulted in a negative prognostic factor for recurrence, independent to FIGO-stage. Positive-LVSI presented an important correlation with distant recurrence compared to women with negative-LVSI and only pelvic recurrences. Risk factors are important to define prognostic risk groups and adjuvant therapy.

246

SURVIVAL OF ELDERLY PATIENTS WITH ENDOMETRIAL CANCER – PREDICTED BY PREOPERATIVE G-8 GERIATRIC SCREENING TOOL

¹K Anic*, ¹C Altheoerfer, ¹MW Schmidt, ¹S Krajnak, ¹R Schwab, ¹V Linz, ²C Westphalen, ³EK Hartmann, ¹M Schmidt, ¹A Hasenburg, ¹M Battista. ¹University Medical Centre of the Johannes Gutenberg University Mainz, Department of Gynaecology and Obstetrics, Mainz, GERMANY; ²University Medical Centre of the Johannes Gutenberg University Mainz, Department of Geriatric Medicine, Mainz, GERMANY; ³University Medical Centre of the Johannes Gutenberg University Mainz, Department of Anesthesiology, Mainz, GERMANY

10.1136/ijgc-2021-ESGO.128

Introduction/Background* We evaluated the prognostic impact of various global health assessment tools in accordance to conventional prognostic factors in patients with endometrial cancer (EC) older than 60 years.

Methodology G-8 geriatric screening tool (G-8 geriatric score), Lee Schonberg prognostic index (Lee-Index), Charlson Comorbidity Index (CCI) and American Society of Anesthesiologists (ASA-PS) – Physical Status System were retrospectively determined in a consecutive cohort of elderly patients with EC. Univariate and multivariate Cox regression analyses and Kaplan-Meier method were performed to determine the impact of the global health assessment tools on progression free survival (PFS) and overall survival (OS).

Result(s)* 153 patients entered the study. In multivariate analysis adjusted for common clinical-pathological risk factors (e.g. histological type and stadium, histological grading, FIGO-stadium, tumor stadium and postoperative tumor burden) and different global health assessment tools (G-8 geriatric score, Lee-Index, CCI and ASA-PS) only the G-8 geriatric score retained its significance as a considerable and independent prognostic factor of 5-year OS rate (HR: 3.173; 95%-CI [1.436-7.010]; p=0.004) but not for univariate 5-year PFS rate (HR: 2.033; 95%-CI [0.925-4.468]; p=0.078). 92 patients (61.3%) were assigned to the G-8-non-frail cohort (cut-off value > 14 points) with an increased 5-year PFS and OS rate compared to the 58 patients (38.7%) classified as G-8-frail (PFS: 82.1% vs. 65.4%; p=0.071 and OS: 88.2% vs. 49.7%; p<0.0001, respectively).

Conclusion* Preoperative G-8 geriatric score independently predicted 5-year OS in elderly EC patients irrespectively of the maximal surgical effort.

252

TYPE OF SENTINEL LYMPH NODES METASTASES AND ONCOLOGIC OUTCOMES IN ENDOMETRIAL CANCER PATIENTS: AN ITALIAN MULTI-INSTITUTIONAL STUDY

¹F Martinelli*, ²A Buda, ³F Fanfani, ⁴F Legge, ⁵M Rocco, ⁶F Falcone, ⁷AM Perrone, ⁸J Casarin, ⁹A Perutelli, ¹⁰N Biglia, ¹¹P Scollo, ¹²F Romano, ¹A Ditto, ²D Ferrari, ³G Monterossi, ⁴F Murgia, ²C Paniga, ³G Scambia, ¹F Raspagliesi. ¹Fondazione IRCCS Istituto Nazionale Tumori di Milan, Gynecologic Oncology, Milan, Italy; ²University of Milan Bicocca, UOC of Gynecology A.O. San Gerardo, Clinic of Obstetrics and Gynecology; ³Fondazione Policlinico Universitario A. Gemelli Università Cattolica del Sacro Cuore; ⁴Ospedale Generale Regionale 'F.Miulli'; ⁵Fondazione IRCCS Policlinico San Matteo, U.O. di Ostetricia e Ginecologia; ⁶Endoscopica Malzoni, Center for Advanced Endoscopic Gynecological Surgery; ⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Oncologic Gynecology; ⁸University of Insubria, Obstetrics and Gynecology Department Del Ponte Women's and Children Hospital; ⁹UO ginecologia 2 di Pisa; ¹⁰Università di Torino SCU Ginecologia e Ostetricia A. O. Ordine Mauriziano Umberto I; ¹¹Ospedale Cannizzaro, AO per l'Emergenza; ¹²Institute for Maternal and Child Health 'IRCCS Burlo Garofolo', Trieste

10.1136/ijgc-2021-ESGO.129

Introduction/Background* The role of volume of sentinel lymph nodes (SLNs) disease (macro-micrometastases and ITCs) in endometrial cancer is not clearly defined. We aimed to asses predictive factors for SLNs involvement and recurrence free survival (RFS) in patients with endometrial cancer.

Methodology A multicenter retrospective evaluation of endometrial cancer patients with positive (macro-micro metastases or ITCs) SLNs, treated between 2003 and 2020, was performed. Predictive factors for nodal involvement (endometrioid vs non-endometrioid histology, grading, lymphovascular-space invasion (LVSI), myometrial invasion (MI), cervical stromal invasion, ESGO/ESTRO/ESP risk group), adjuvant therapy and oncological outcomes were evaluated.